November 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Keyora Lycopene 23 in 1 Man's Multi-Vitamin improves male reproductive health and metabolism.
13 citations
,
May 2011 in “Bioorganic & Medicinal Chemistry” Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.
21 citations
,
November 2018 in “Journal of the European Academy of Dermatology and Venereology” The combination of encorafenib and binimetinib caused few skin issues.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
3 citations
,
January 2006 in “Eclética Química” Three cost-effective methods accurately measure finasteride in pharmaceuticals, better than current techniques.
September 2023 in “International journal of molecular sciences” Pinus densiflora extract may help improve memory and reduce brain inflammation.
Cepharanthine and tetrandrine show promise as COVID-19 drugs.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
8 citations
,
July 2023 in “Frontiers in Pharmacology” Cepharanthine shows promise as a COVID-19 treatment.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
24 citations
,
March 1998 in “Mycoses” Early diagnosis and effective treatment of kerion Celsi prevent scarring and permanent hair loss.
14 citations
,
May 2022 in “International Journal of Molecular Sciences” Platelet-rich plasma improves bladder function and reduces overactivity in ketamine-induced bladder issues.
August 2023 in “Journal of Chromatographic Science” A new method accurately measures three compounds in rat plasma from pine needle extracts, aiding future research on its use for hair loss.
7 citations
,
April 1996 in “Archives of dermatological research” Topical tacalcitol can treat psoriasis by acting directly on skin cells.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
January 2026 in “Cell and Tissue Biology” TS-13 speeds up hair regrowth after chemotherapy without affecting treatment effectiveness.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.
February 2026 in “Eduvest - Journal Of Universal Studies” Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
23 citations
,
June 2017 in “Drug Design Development and Therapy” Cyclodextrins improve finasteride's solubility and bioavailability for hair loss treatment.
October 2020 in “Journal of Pharmaceutical Sciences” Topical finasteride with EGCG or TA improves drug release and dermal uptake, potentially treating hair loss effectively.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.